---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-007667"
form_type: "8-K"
ticker: "DWTX"
cik: "0001818844"
company_name: "Dogwood Therapeutics, Inc."
filed_at: "2023-05-02T23:59:59+00:00"
generated_at: "2026-06-16T03:46:52.536172+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Virios Therapeutics gets Nasdaq bid-price extension to Oct 30, 2023

## Summary
- Received extension letter on May 2, 2023; new compliance period ends Oct 30, 2023.
- Company meets all other Nasdaq listing requirements except $1.00 minimum bid price.
- Intends to cure deficiency via reverse stock split if necessary.
- If not compliant by Oct 30, 2023, Nasdaq could delist; company may appeal to Hearings Panel.
- No assurance of regaining compliance or maintaining Nasdaq listing.

## SEC filing metadata
- accession: 0001558370-23-007667
- form_type: 8-K
- ticker: DWTX
- cik: 0001818844
- company_name: Dogwood Therapeutics, Inc.
- filed_at: 2023-05-02T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818844/000155837023007667/0001558370-23-007667-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818844/000155837023007667/tmb-20230502x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-007667
- JSON: https://secwatch.observer/filing/0001558370-23-007667.json
- Plain text: https://secwatch.observer/filing/0001558370-23-007667.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.